Experience with the use of trastuzumab deruxtecan in real-world clinical practice: data from Clinical Oncology Dispensary no. 1 (Krasnodar) and Federal Scientific Clinical Center of the fMBA of Russia
Open Access
- 2 September 2026
- journal article
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (2) , 49-61
Abstract
This article presents a systematic review of international and domestic experience with the use of trastuzumab deruxtecan in patients with HER2-positive and HER2-low metastatic breast cancer. Based on an analysis of key registration studies (DESTINY-Breast01, -03, -04), and confirmatory clinical trials (DESTINY-Breast02, -12) and real-world clinical practice data from the Clinical Oncology Dispensary No. 1 (Krasnodar) (n = 22) and Federal Scientific Clinical Center of the Federal Medical and Biological Agency of Russia (n = 6), the article summarizes the specifics of drug administration in the Russian healthcare setting, its efficacy profile, and manageable toxicity. A clinical case of a patient with HER2-positive mBC and brain metastases is described in detail, demonstrating long-term disease control (more than 15 months) with trastuzumab deruxtecan therapy in the second line after progression during treatment with a combination of trastuzumab, pertuzumab, and docetaxel. Practical recommendations for clinicians on monitoring the key adverse event – interstitial lung disease and pneumonitis – have been formulated.Keywords
This publication has 19 references indexed in Scilit:
- Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNature Medicine, 2024
- Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyBreast Cancer, 2024
- Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trialESMO Open, 2024
- Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)npj Breast Cancer, 2023
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialThe Lancet, 2022
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerNew England Journal of Medicine, 2022
- The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based studyInternational Journal of Clinical Oncology, 2022
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerNew England Journal of Medicine, 2020
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2015